Daniel M. Halperin, M.D.
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
About Dr. Halperin
Dr. Halperin is a medical oncologist and clinical investigator primarily focused on the development of novel treatments for patients with neuroendocrine tumors (NETs). He serves as chair of the NET Multidisciplinary Conference (Tumor Board) at MD Anderson, and represents the institution on the the Neuroendocrine and Adrenal Tumor guideline committee of the National Comprehensive Cancer Network (NCCN).
As a clinical investigator, he leads clinical trials of new drugs for patients with NETs at MD Anderson, and works together with a team of laboratory and population scientists to understand more fully the molecular underpinnings and clinical manifestations of neuroendocrine tumors. He serves on the Board of Scientific Advisors of the NET Research Foundation and the Scientific Advisory Committee of the Healing NET Foundation, as well as chairing the North American Neuroendocrine Tumor Society Scientific and Research Committee in 2021.
Ongoing clinical trials include:1. Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2) ( NCT03972488).
2. A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (SORENTO) ( NCT05050942). [Not yet recruiting]
In the News
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Clinical Medical Director, Gastrointestinal Center, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2009 | Weill Cornell Medical College, New York, NY, USA, MD, Medicine |
| 2004 | Massachusetts Institute of Technology, Cambridge, MA, USA, BS, Biology |
Postgraduate Training
| 2012-2015 | Clinical Fellowship, Medical Oncology, MD Anderson Cancer Center, Houston, TX |
| 2009-2012 | Clinical Residency, Internal Medicine, Brigham and Women's Hospital, Boston, MA |
Board Certifications
| 2015 | ABIM: Medical Oncology |
| 2013 | ABIM: Internal Medicine |
Experience & Service
Academic Appointments
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2021
Clinical Fellow, Division of Internal Medicine, Harvard Medical School, Boston, MA, 2009 - 2012
Other Appointments/Responsibilities
Member, MD Anderson Rare Tumor Working Group, Houston, TX, 2016 - Present
Institutional Committee Activities
Member, Institutional Review Board, 2021 - Present
Member, Investigational New Drug Committee, 2020 - 2021
Chair, Neuroendocrine Tumor Multidisciplinary Conference, 2020 - Present
Member, Demand Generation Committee, 2018 - 2019
Member, Scientific Research Committee, 2018 - 2021
Member, MD Anderson Cancer Center House Staff Senate, 2014 - 2015
Honors & Awards
| 2018 | American Society of Clinical Oncology Career Development Award |
| 2015 | Waun Ki Hong Award for Clinical Investigation, MD Anderson Cancer Center |
| 2014 | Resident Recognition Award, Harvard Medical School |
| 2012 | Novartis Advanced Scholar in Neuroendocrine Tumors, MD Anderson Cancer Center |
| 2009 | Coryell Prize, Weill Cornell Medical College |
| 2008 | Alpha Omega Alpha Honor Medical Society |
| 2006 | Research Training Fellowship for Medical Students, Howard Hughes Medical Institute |
| 2002 | Research Experience for Undergraduates Scholarship, National Science Foundation |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Rogers JE, Lam M, Halperin DM, Dagohoy CG, Yao JC, Dasari A. FAS and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology 112(1):34-42, 2022. e-Pub 2021. PMID: 33434908.
- Fujii Y, Tzeng CW, Chiang YJ, Halperin DM, Dasari A, Kim MP, Katz MHG, Lee JE, Ikoma N. Incidence of Lymph Node Metastases and Impact of Radical Surgery for Duodenal Neuroendocrine Tumors. J Surg Res 268:419-431, 2021. e-Pub 2021. PMID: 34416414.
- Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov 11(11):2738-2747, 2021. e-Pub 2021. PMID: 34261675.
- Fahrmann JF, Wasylishen AR, Pieterman CRC, Irajizad E, Vykoukal J, Murage E, Wu R, Dennison JB, Krishna H, Peterson CB, Lozano G, Zhao H, Do KA, Halperin DM, Agarwal SK, Blau JE, Del Rivero J, Nilubol N, Walter MF, Welch JM, Weinstein LS, Vriens MR, van Leeuwaarde RS, van Treijen MJC, Valk GD, Perrier ND, Hanash SM. A blood-based polyamine signature associated with MEN1 duodenopancreatic neuroendocrine tumor progression. J Clin Endocrinol Metab 106(12):e4969-e4980, 2021. e-Pub 2021. PMID: 34318891.
- Pan IW, Halperin DM, Kim B, Yao JC, Shih YT. A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. Pharmacoeconomics 39(11):1271-1297, 2021. e-Pub 2021. PMID: 34378163.
- Das S, Du L, Lee CL, Arhin ND, Chan JA, Kohn EC, Halperin DM, Berlin J, LaFerriere H, Singh S, Kunz PL, Dasari A. Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. JAMA Netw Open 4(10):e2131744, 2021. e-Pub 2021. PMID: 34705010.
- Kadakia KT, Halperin DM, Offodile AC. Operationalizing Virtual Trials in Oncology-From Aspiration to Action. JCO Clin Cancer Inform 5:953-957, 2021. PMID: 34516277.
- Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19(7):839-868, 2021. e-Pub 2021. PMID: 34340212.
- Shaunfield S, Webster KA, Kaiser K, Greene GJ, Yount SE, Lacson L, Benson AB, Halperin DM, Yao JC, Singh S, Feuilly M, Marteau F, Cella D. Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index (FACT-CSI). Neuroendocrinology 111(9):850-862, 2021. e-Pub 2020. PMID: 32911478.
- Hernandez Vargas S, Lin C, Voss J, Ghosh SC, Halperin DM, AghaAmiri S, Cao HST, Ikoma N, Uselmann AJ, Azhdarinia A. Development of a drug-device combination for fluorescence-guided surgery in neuroendocrine tumors. J Biomed Opt 25(12), 2020. PMID: 33300316.
- Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. Expert Rev Pharmacoecon Outcomes Res 20(5):1-5, 2020. e-Pub 2019. PMID: 31448649.
- Eads JR, Reidy-Lagunes D, Soares HP, Chan JA, Anthony LB, Halfdanarson TR, Naraev BG, Wolin EM, Halperin DM, Li D, Pommier RF, Zacks JS, Morse MA, Metz DC, from the Carcinoid Syndrome Control Collaborative. Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. Pancreas 49(9):1123-1130, 2020. PMID: 32991344.
- Tang T, Abu-Sbeih H, Ma W, Lu Y, Luo W, Foo WC, Richards DM, Halperin DM, Ge PS, Wang Y. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. Clin Colorectal Cancer 19(3):e117-e123, 2020. e-Pub 2020. PMID: 32284253.
- Pieterman CRC, Sadowski SM, Maxwell JE, Katz MHG, Lines KE, Heaphy CM, Tirosh A, Blau JE, Perrier ND, Lewis MA, Metzcar JP, Halperin DM||, Thakker RV, Valk GD. MEN1-related PanNETs: identifying unmet clinical needs and future directives. Endocr Relat Cancer 27(8):T9-T25, 2020. e-Pub 2020. PMID: 32069215.
- Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas 49(7):863-881, 2020. PMID: 32675783.
- Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas 49(6):723-728, 2020. PMID: 32433264.
- Vijayvergia N, Dasari A, Deng M, Litwin S, Al-Toubah T, Alpaugh RK, Dotan E, Hall MJ, Ross NM, Runyen MM, Denlinger CS, Halperin DM, Cohen SJ, Engstrom PF, Strosberg JR. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. Br J Cancer 122(9):1309-1314, 2020. e-Pub 2020. PMID: 32152503.
- Abu-Sbeih H, Mallepally N, Goldstein R, Chen E, Tang T, Dike UK, Al-Asadi M, Westin S, Halperin D, Wang Y. Gastrointestinal toxic effects in patients with cancer receiving platinum-based therapy. J Cancer 11(11):3144-3150, 2020. e-Pub 2020. PMID: 32231718.
- Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Direct costs of carcinoid syndrome diarrhea among adults in the United States. World J Gastroenterol 25(47):6857-6865, 2019. PMID: 31885426.
- Shen C, Dasari A, Chu Y, Halperin DM, Zhou S, Xu Y, Shih YT, Yao JC. Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors. Ann Oncol 30(11):1847, 2019. PMID: 31407007.
- Shen C, Gu D, Zhou S, Xu Y, Sarshekeh AM, Halperin D, Shih YT, Yao JC, Dasari A. Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors. Pancreas 48(10):1373-1379, 2019. PMID: 31688604.
- Naraev BG, Halland M, Halperin DM, Purvis AJ, O'Dorisio TM, Halfdanarson TR. Management of Diarrhea in Patients With Carcinoid Syndrome. Pancreas 48(8):961-972, 2019. PMID: 31425482.
- Balanescu DV, Donisan T, Lopez-Mattei J, Hassan S, Kim P, Dasari A, Halperin D, Yao J, Kar B, Gregoric I, Balanescu SM, Iliescu C. The 1, 2, 3, 4 of carcinoid heart disease: Comprehensive cardiovascular imaging is the mainstay of complex surgical treatment. Oncol Lett 17(5):4126-4132, 2019. e-Pub 2018. PMID: 30944605.
- Samdani RT, Wasylishen AR, Halperin DM, Dasari A, Yao JC, Rashid A, Estrella JS. Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors: Comparison Between Primary and Metastatic Tumors. Pancreas 48(4):510-513, 2019. e-Pub 2019. PMID: 30946241.
- Halperin DM, Lee JJ, Ng CS, Strosberg JR, Estrella JS, Dagohoy CG, Dasari A, Yao JC. A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas 48(3):381-386, 2019. e-Pub 2019. PMID: 30768575.
- Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak RH, Narkhede S, Totev T, Duh MS, Neary MP, Cella D. Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome. BMC Cancer 19(1):274, 2019. e-Pub 2019. PMID: 30922252.
- Serpas VJ, Raghav KP, Halperin DM, Yao J, Overman MJ. Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology. BMC Med Res Methodol 18(1):169, 2018. e-Pub 2018. PMID: 30541475.
- Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak RH, Duh MS, Neary MP, Cella D. Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study. Medicine (Baltimore) 97(47):e13390, 2018. PMID: 30461659.
- Shen C, Dasari A, Xu Y, Zhou S, Gu D, Chu Y, Halperin DM, Shih YT, Yao JC. Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study. Sci Rep 8(1):16863, 2018. e-Pub 2018. PMID: 30442902.
- Shen C, Dasari A, Gu D, Chu Y, Zhou S, Xu Y, Halperin D, Fu S, Yao JC, Shih YT. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics 36(8):1005-1013, 2018. e-Pub 2018. PMID: 29682693.
- Cloyd JM, Omichi K, Mizuno T, Kawaguchi Y, Tzeng CD, Conrad C, Chun YS, Aloia TA, Katz MHG, Lee JE, Halperin D, Yao J, Vauthey JN, Dasari A. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. Ann Surg Oncol 25(6):1709-1715, 2018. e-Pub 2018. PMID: 29626307.
- Shen C, Chu Y, Halperin DM, Dasari A, Zhou S, Xu Y, Yao JC, Shih YT. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist 22(12):1451-1462, 2017. e-Pub 2017. PMID: 28642335.
- Sarshekeh AM, Advani S, Halperin DM, Conrad C, Shen C, Yao JC, Dasari A. Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. Oncotarget 8(59):99541-99551, 2017. e-Pub 2017. PMID: 29245922.
- Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 3(10):1335-1342, 2017. e-Pub 2017. PMID: 28448665.
- Nejati R, Goldstein JB, Halperin DM, Wang H, Hejazi N, Rashid A, Katz MH, Lee JE, Fleming JB, Rodriguez-Canales J, Blando J, Wistuba II, Maitra A, Wolff RA, Varadhachary GR, Wang H. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Pancreas 46(9):1180-1187, 2017. PMID: 28902789.
- Shen C, Dasari A, Chu Y, Halperin DM, Zhou S, Xu Y, Shih YT, Yao JC. Clinical, pathological and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors. Ann Oncol 28(7):1582-1589, 2017. e-Pub 2017. PMID: 28444105.
- Qiu W, Christakis I, Stewart AA, Vodopivec DM, Silva-Figueroa A, Chen H, Woodard TL, Halperin DM, Lee JE, Yao JC, Perrier ND. Is estrogen exposure a protective factor for pancreatic neuroendocrine tumors in female multiple endocrine neoplasia syndrome type 1 patients?. Clin Endocrinol (Oxf) 86(6):791-797, 2017. e-Pub 2017. PMID: 28273369.
- Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, Shih YT, Yao JC. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 18(4):525-534, 2017. e-Pub 2017. PMID: 28238592.
- Prakash L, Bhosale P, Cloyd J, Kim M, Parker N, Yao J, Dasari A, Halperin D, Aloia T, Lee JE, Vauthey JN, Fleming JB, Katz MH. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 21(1):155-163, 2017. e-Pub 2016. PMID: 27634306.
- Halperin DM, Lee JJ, Dagohoy CG, Yao JC. Rational Clinical Experiment: Assessing Prior Probability and its Impact on the Success of Phase II Clinical Trials. J Clin Oncol 33(26):2914-9, 2015. e-Pub 2015. PMID: 26261263.
- Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol 16(6):695-703, 2015. e-Pub 2015. PMID: 25956795.
- Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocr Relat Cancer 22(3):431-41, 2015. e-Pub 2015. PMID: 25900182.
- Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM. A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer 14:561, 2014. e-Pub 2014. PMID: 25086465.
- Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, Czura CJ, Fink MP, Tracey KJ. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A 99(19):12351-6, 2002. e-Pub 2002. PMID: 12209006.
- Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, Pusceddu S, Reising A, Degtyarev E, Shilkrut M, Eddy S, Singh S. Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. Endocr Relat Cancer. e-Pub 2021. PMID: 33480358.
- Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, Bergsland EK, Morani AC. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms. Abdom Radiol (NY). e-Pub 2020. PMID: 33095312.
- Grubbs EG, Halperin DM, Waguespack SG, Gagel RF. History of the multiple endocrine neoplasia workshops and overview of MEN2019. Endocr Relat Cancer. e-Pub 2020. PMID: 32508314.
Invited Articles
- Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw 16(6):693-702, 2018. PMID: 29891520.
- Halperin DM, Dasari A, Yao JC. Future Directions in the Biology of Neuroendocrine Tumors. Pancreas 45(6):783-5, 2016. PMID: 27295529.
- Mehrvarz Sarshekeh A, Halperin DM, Dasari A. Update on management of midgut neuroendocrine tumors. Int J Endocr Oncol 3(2):175-189, 2016. e-Pub 2016. PMID: 27347369.
- Halperin DM, Yao JC. Clinical trial design in neuroendocrine tumors. Hematol Oncol Clin North Am 30(1):209-17, 2016. PMID: 26614378.
- Halperin DM, Kulke MH, Yao JC. A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors. Annu Rev Med 66:1-16, 2015. e-Pub 2014. PMID: 25341008.
- Halperin DM, Varadhachary GR. Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter?. Curr Oncol Rep 16(2):366, 2014. PMID: 24445498.
- Halperin DM, Kulke MH. Management of pancreatic neuroendocrine tumors. Gastroenterol Clin North Am 41(1):119-31, 2012. PMID: 22341253.
- Halperin DM, Dasari A, Yao JC. [(177)Lu-DOTA(0),Tyr(3)]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncol. e-Pub 2016. PMID: 26759064.
Editorials
- Halperin DM, Yao JC, Dasari A. What's in a Name? Steady Progress in Staging Pancreatic Neuroendocrine Tumors. J Clin Oncol 35(3):JCO2016707364, 2017. PMID: 27893328.
Book Chapters
- Halperin DM, Yao JC. Neuroendocrine Tumors. In: The MD Anderson Manual of Medical Oncology. 3. McGraw-Hill: China, 537-551, 2016.
Letters to the Editor
- Halperin DM, Shen C, Yao JC. Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? - Authors' reply. Lancet Oncol 18: e300, 2017.
Grant & Contract Support
| Title: | Multidimensional Immune Profiling of Advanced Pancreatic Neuroendocrine Tumors |
| Funding Source: | Neuroendocrine Tumor Research Foundation |
| Role: | Principal Investigator |
| Title: | Harnessing the Immune System in Neuroendocrine Tumors |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Principal Investigator |
| Title: | Chromogranin A as Surveillance biomarker |
| Funding Source: | BRAHMS GmbH |
| Role: | Principal Investigator |
| Title: | Tumor-Specific Delivery of Temozolomide to Overcome Resistance in GEP-NETS |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Collaborator |
| Title: | CCSG supplement: Creating an efficient clinical trial build system via the Clinical Trials Rapid Activation Consortium (CTRAC) |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |